Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Denali Therapeutics (DNLI) Total Current Liabilities (2017 - 2026)

Denali Therapeutics has reported Total Current Liabilities over the past 9 years, most recently at $98.4 million for Q4 2025.

  • Quarterly Total Current Liabilities fell 3.77% to $98.4 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $98.4 million through Dec 2025, down 3.77% year-over-year, with the annual reading at $98.4 million for FY2025, 3.77% down from the prior year.
  • Total Current Liabilities was $98.4 million for Q4 2025 at Denali Therapeutics, up from $90.1 million in the prior quarter.
  • Over five years, Total Current Liabilities peaked at $391.1 million in Q1 2023 and troughed at $51.4 million in Q2 2021.
  • The 5-year median for Total Current Liabilities is $90.6 million (2025), against an average of $164.0 million.
  • Year-over-year, Total Current Liabilities surged 577.2% in 2022 and then crashed 80.26% in 2023.
  • A 5-year view of Total Current Liabilities shows it stood at $378.2 million in 2021, then fell by 3.79% to $363.9 million in 2022, then plummeted by 78.57% to $78.0 million in 2023, then soared by 31.07% to $102.2 million in 2024, then fell by 3.77% to $98.4 million in 2025.
  • Per Business Quant, the three most recent readings for DNLI's Total Current Liabilities are $98.4 million (Q4 2025), $90.1 million (Q3 2025), and $91.1 million (Q2 2025).